|
|
 |
FD&C BLUE NO. 1 Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
EUCRISA Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
BEYAZ Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ETHYLCELLULOSES Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
FD&C BLUE NO. 2 Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|